Galectin Therapeutics (GALT) Shares Outstanding (2010 - 2026)

Galectin Therapeutics has reported Shares Outstanding for 17 years, with the latest figure at $65.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 4.05% year-over-year to $65.9 million; the trailing twelve-month figure through Mar 2026 stood at $65.9 million (up 4.05% YoY), and the FY2025 full-year result was $65.2 million, up 5179.51% from the prior year.
• Shares Outstanding for Q1 2026 stood at $65.9 million, up from $65.2 million in the prior quarter.
• The five-year high for Shares Outstanding was $65.9 million in Q1 2026, with the low at $1.2 million in Q2 2025.
• Average Shares Outstanding over 5 years is $37.1 million, with a median of $59.4 million recorded in 2022.
• Year-over-year, Shares Outstanding tumbled 98.0% in 2024 and soared 5179.51% in 2025.
• Tracing GALT's Shares Outstanding over 5 years: stood at $1.3 million in 2022, then decreased by 1.98% to $1.2 million in 2023, then changed by 0.0% to $1.2 million in 2024, then soared by 5179.51% to $65.2 million in 2025, then increased by 1.0% to $65.9 million in 2026.
• The last three Shares Outstanding figures came in at $65.9 million (Q1 2026), $65.2 million (Q4 2025), and $64.5 million (Q3 2025), per Business Quant data.

Peer Comparison